JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

68.93 0.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.45

Max

70.04

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.5M -190M
Verkoop	33M 154M
Winstmarge	-123.403
Werknemers	834
EBITDA	-6.9M -180M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+52.2% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	361M 13B
Vorige openingsprijs	68.9
Vorige sluitingsprijs	68.93

Nieuwssentiment

By Acuity

19%

81%

50 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.71 / 36.9 Steun & Weerstand

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mei 2026, 23:43 UTC

Belangrijke Nieuwsgebeurtenissen

New Zealand's Unemployment Rate Falls in 1Q

5 mei 2026, 23:20 UTC

Populaire aandelen

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mei 2026, 21:48 UTC

Winsten

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mei 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mei 2026, 00:00 UTC

Marktinformatie

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mei 2026, 22:26 UTC

Marktinformatie

AMD Data-Center Business Continues to Surge -- Market Talk

5 mei 2026, 22:20 UTC

Marktinformatie

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mei 2026, 22:08 UTC

Winsten

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mei 2026, 22:07 UTC

Winsten

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mei 2026, 21:48 UTC

Winsten

Pan American Silver 1Q Rev $1.2B >PAAS

5 mei 2026, 21:42 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:38 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:30 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:29 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:26 UTC

Winsten

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mei 2026, 21:25 UTC

Winsten

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mei 2026, 21:24 UTC

Winsten

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mei 2026, 21:18 UTC

Winsten

Mistras Backs 2026 Rev $730M-$750M >MG

5 mei 2026, 21:17 UTC

Winsten

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mei 2026, 21:15 UTC

Winsten

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mei 2026, 21:12 UTC

Winsten

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mei 2026, 21:11 UTC

Winsten

SSR Mining 1Q Rev $581.8M >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mei 2026, 21:10 UTC

Winsten

SSR Mining 1Q EPS $1.16 >SSRM

5 mei 2026, 21:08 UTC

Winsten

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mei 2026, 21:01 UTC

Winsten

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mei 2026, 21:01 UTC

Populaire aandelen

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

52.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 105 USD 52.2%

Hoogste 157 USD

Laagste 81 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

50 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.